BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16331255)

  • 1. Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control.
    Sánchez-Aguilera A; García JF; Sánchez-Beato M; Piris MA
    Oncogene; 2006 Apr; 25(18):2565-74. PubMed ID: 16331255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
    Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
    Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.
    García JF; Villuendas R; Sánchez-Beato M; Sánchez-Aguilera A; Sánchez L; Prieto I; Piris MA
    Am J Pathol; 2002 Feb; 160(2):569-78. PubMed ID: 11839577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
    Heminger K; Markey M; Mpagi M; Berberich SJ
    Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability.
    Dias CS; Liu Y; Yau A; Westrick L; Evans SC
    Cancer Res; 2006 Oct; 66(19):9467-73. PubMed ID: 17018602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma.
    Gibcus JH; Kroesen BJ; Koster R; Halsema N; de Jong D; de Jong S; Poppema S; Kluiver J; Diepstra A; van den Berg A
    J Pathol; 2011 Dec; 225(4):609-17. PubMed ID: 21953646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.
    Evans SC; Viswanathan M; Grier JD; Narayana M; El-Naggar AK; Lozano G
    Oncogene; 2001 Jul; 20(30):4041-9. PubMed ID: 11494132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of spliced variants of the proto-oncogene HDM2 in colorectal cancer.
    Yu Z; Zhang B; Cui B; Wang Y; Han P; Wang X
    Cancer; 2012 Feb; 118(4):1110-8. PubMed ID: 21761395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma.
    Feuerborn A; Möritz C; Von Bonin F; Dobbelstein M; Trümper L; Stürzenhofecker B; Kube D
    Leuk Lymphoma; 2006 Sep; 47(9):1932-40. PubMed ID: 17065008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.
    Giglio S; Mancini F; Gentiletti F; Sparaco G; Felicioni L; Barassi F; Martella C; Prodosmo A; Iacovelli S; Buttitta F; Farsetti A; Soddu S; Marchetti A; Sacchi A; Pontecorvi A; Moretti F
    Cancer Res; 2005 Nov; 65(21):9687-94. PubMed ID: 16266988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
    Phelps M; Darley M; Primrose JN; Blaydes JP
    Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
    Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
    J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA.
    Phillips A; Blaydes JP
    Oncogene; 2008 Mar; 27(11):1645-9. PubMed ID: 17828301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm.
    Phelps M; Phillips A; Darley M; Blaydes JP
    J Biol Chem; 2005 Apr; 280(17):16651-8. PubMed ID: 15723837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.
    Willenbrock K; Küppers R; Renné C; Brune V; Eckerle S; Weidmann E; Bräuninger A; Hansmann ML
    Haematologica; 2006 May; 91(5):596-604. PubMed ID: 16670065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
    Moumen A; Masterson P; O'Connor MJ; Jackson SP
    Cell; 2005 Dec; 123(6):1065-78. PubMed ID: 16360036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of the oncoprotein prothymosin alpha triggers a p53 response that involves p53 acetylation.
    Kobayashi T; Wang T; Maezawa M; Kobayashi M; Ohnishi S; Hatanaka K; Hige S; Shimizu Y; Kato M; Asaka M; Tanaka J; Imamura M; Hasegawa K; Tanaka Y; Brachmann RK
    Cancer Res; 2006 Mar; 66(6):3137-44. PubMed ID: 16540664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2.
    Linares LK; Kiernan R; Triboulet R; Chable-Bessia C; Latreille D; Cuvier O; Lacroix M; Le Cam L; Coux O; Benkirane M
    Nat Cell Biol; 2007 Mar; 9(3):331-8. PubMed ID: 17293853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.